{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.15","upperLimit":"4.73","value":"2.04"},{"groupId":"OG001","lowerLimit":"0.95","upperLimit":"5.52","value":"1.45"},{"groupId":"OG002","lowerLimit":"0.95","upperLimit":"5.52","value":"1.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"TTR was defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that was subsequently confirmed.","dispersionType":"Full Range","groups":[{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Phase 1b"},{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG001","title":"Phase 2"},{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG002","title":"Phase 1b + Phase 2"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set included all enrolled participants who received at least 1 dose of study intervention. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure","reportingStatus":"POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurs first (approximately up to 16 months)","title":"Time-to-Response (TTR) as Per IMWG Criteria by BICR","type":"SECONDARY","unitOfMeasure":"Months"}